Cabozantinib versus sunitinib for previously untreated patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk: subgroup analysis of progression-free survival (PFS) and objective response rate (ORR) in the Alliance A031203 CABOSUN trial
- Citation:
- J Clin Oncol vol 36 (suppl 6S) abstr 582
- Meeting Instance:
- ASCO GU 2018
- Year:
- 2018
- Type:
- Abstract
- Sub type:
- Oral
- Funding:
- NCTN
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- epreprint
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- 2834
- Pharmas:
- Grants:
- U10CA180821, U10CA180882
- Corr. Author:
- Authors:
- Daniel George Colin Hessel Susan Halabi Ben Sanford M. Dror Michaelson Olwen Hahn Meghara Walsh Thomas Olencki Joel Picus Eric J. Small Shaker Dakhil Darren Feldman Milan Mangeshkar Christian Scheffold Michael J. Morris Toni K. Choueiri
- Networks:
- CA136, KS055, LAPS-IL057, LAPS-MA036, LAPS-MO011, LAPS-NC010, LAPS-NY016, LAPS-OH007
- Study
- Alliance-A031203
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords: